_Planning for Cell & Gene Therapy Commercialization      (5)


Planning for Cell & Gene Therapy Commercialization   

A panel discussion with:

  • Matt Booth, SVP Global Therapy Lead, ApotheCom, An Inizio Company
  •  Ben Beckley, President, Evoke Mind + Matter, An Inizio Company 
  •  Dean McAlister, EVP, Inizio Biotech 
  •  Greg Christianson, Principal, Nuvera, An Inizio Company
  •  Rita Johnson-Greene, COO, Alliance for Regenerative Medicine (ARM) 

Bringing cell & gene therapies to market is no easy feat. The many technicalities involved in running trials, scaling manufacturing capabilities, market access and launch drives up end-to-end costs, meaning patients are often faced with a complex, long and expensive road to treatment.

With the aim to bring CGT’s to as many patients as possible, panellists discuss the early-commercial planning factors facing CGT companies today and tried-and-tested solutions.

Watch now




In partnership with

Inizio Biotech Logo

Inizio unlocks the value of your healthcare innovation by connecting best-in-class strategic, analytic, and creative capabilities. By bridging our scientific knowledge, market intelligence, actionable data, cutting-edge technology, and creative execution, Inizio is by your side to help you confidently navigate the complex asset lifecycle, rising to any challenges together.